Transthyretin-related familial amyloid polyneuropathy (FAP), a fatal hereditary amyloidosis, is characterized by systemic accumulation of mutant amyloidogenic transthyretin (ATTR) in peripheral nerves and several organs.
1,2 Liver transplantation has been believed to be a promising method for halting the progression of neurologic complications in patients with transthyretin-related FAP inasmuch as the liver is the primary synthetic source of ATTR found in serum.
3,4 However, ocular complications have reportedly continued and worsened even after liver transplantation
5,6 because ocular tissues, mainly retinal pigment epithelium (RPE), also synthesized ATTR.
7,8 Detection of a significant amount of ATTR in aqueous humor and vitreous from patients with FAP after liver transplantation has previously been reported.
9,10